Record sales and orders drove double-digit EPS growth, with strong performance in Health & Science Technologies and robust cash flow. Full-year guidance was raised on the back of broad-based demand and margin expansion, despite some segmental softness.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.